Suggested remit: To appraise the clinical and cost effectiveness of emicizumab within its marketing authorisation for preventing bleeding episodes in people with mild or moderate haemophilia A without inhibitors.
- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The chair of TSOP has confirmed that it would not be an efficient use of NHS resources to conduct an evaluation at this time. Because emicizumab is covered by an existing NHS England clinical commissioning policy, NHS England have confirmed that this indication may be considered for routine commissioning.
- ID number:
- 5098
Project Team
- Project lead
- Abigail Stephens
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 February 2023 | Topic selection. Changed back to TS to reflect TSOP not selected decision |
| 16 February 2023 | Topic selection |
| 04 November 2022 - 02 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 07 July 2022 | In progress. DHSC referral received |
| 05 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about prioritising our guidance topics